What experts said about CJC-1295 in Q2 2026

Between March and June 2026, the public conversation around CJC-1295 shifted from pharmacology to regulation. The peptide was removed from the FDA's Category 2 bulk-substance list on April 15, 2026, and the Pharmacy Compounding Advisory Committee is scheduled to review it on July 23-24, 2026 alongside ipamorelin and other grey-market peptides. In parallel, three peer-reviewed papers published in 2026 assessed CJC-1295's evidence base for musculoskeletal and sports-medicine use, and a cardiologist's widely circulated essay flagged a class-level cancer concern that applies to all growth-hormone secretagogues. This digest collects the on-record expert commentary, notes credentials and conflicts of interest, and lets readers compare the positions side by side.

The clinical evidence gap: three reviews, one conclusion

Cory Mayfield and colleagues at USC published a primer on injectable peptide therapy in the American Journal of Sports Medicine in January 2026. Their review found that CJC-1295 combined with ipamorelin "showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, but these findings are limited to animal studies." Their conclusion was unambiguous: "significant research regarding the safety and efficacy of these therapeutic methods is required before definitive recommendations can be made to patients"^[1].

Omar Rahman, Steven Lee, and William Seeds wrote in the Journal of the American Academy of Orthopaedic Surgeons (January 2026) that CJC-1295 belongs to a group of growth-hormone secretagogues -- alongside ipamorelin, tesamorelin, and sermorelin -- that "activate IGF-1 signaling and satellite cell repair," but added that "preclinical studies are promising" while acknowledging "a current lack of clinical trials"^[2].

The most recent assessment came from Alan Villegas Meza, Marc Philippon, and colleagues at the Steadman Philippon Research Institute, writing in JBJS Reviews in May 2026. Their structured narrative review classified growth-hormone secretagogues including CJC-1295 as compounds that "remain investigational, with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions"^[3].

Remain investigational, with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions.

The cancer concern: Topol's class-level warning

Eric Topol, a cardiologist and editor-in-chief of Medscape, wrote in his Ground Truths newsletter that "growth hormone related peptides (CJC-1295, Ipamorelin, and Tesamorelin) carry the potential risk of cancer" by virtue of "inducing broad cell growth." His broader assessment of the peptide class was sharper still: "there is no evidence from randomized trials in humans that any of these peptides provide the benefits that are advocated"^[4]. Topol drew a deliberate contrast with GLP-1 receptor agonists like semaglutide, which he described as "one of, if not the most rigorously studied class of peptides ever, with many large, placebo-controlled, randomized trials" -- a standard CJC-1295 has never come close to meeting.

The regulatory picture: removed from Category 2, not approved

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr announced that approximately 14 peptides would be moved from the FDA's Category 2 restricted list. On April 15, 2026, the FDA reorganised the bulk-substance lists: CJC-1295 was removed from Category 2 but was not placed on Category 1. The peptide now sits in a regulatory gap with no formal classification, pending PCAC review^[5].

Regulatory attorneys Charles Snow and Karla Palmer at Hyman, Phelps & McNamara wrote in April 2026 that the PCAC meeting is "a necessary procedural step, not the finish line," because "notice-and-comment rulemaking is still required -- a process that, under standard timelines, can take more than a year"^[6]. Some 503A pharmacies have started compounding CJC-1295 on the interpretation that removal from Category 2 lifts the prohibition, but CJC-1295 has no completed New Drug Application, no approved label, and no agency-approved indication. Until the PCAC review concludes and the FDA issues a final classification, compounding occurs in a gap where the legal picture is genuinely uncertain.

Peter Attia's bucket framework

Peter Attia, MD, addressed CJC-1295 as a case study in episode 387 of The Drive (April 13, 2026). He placed CJC-1295 in his "Bucket #2": peptides with a plausible mechanism but limited human data, dosing uncertainty, and a risk-reward profile he considers unfavourable given the lack of long-term safety data^[7]. (COI: Attia operates Early Medical, a longevity clinic; Momentous supplement-line affiliation.)

The anti-doping dimension

CJC-1295 is explicitly named under section S2.2.4 of the 2026 WADA Prohibited List as a growth-hormone-releasing-factor analogue, prohibited in and out of competition. Ucakturk and Nemutlu published a WADA-validated nano-LC quadrupole/orbitrap MS method in the Journal of Pharmaceutical and Biomedical Analysis (January 2026) that can detect CJC-1295 in urine at limits of detection at or below 0.5 ng/mL^[8]. For anyone subject to anti-doping testing, a positive result carries a multi-year ban.

What to make of the quarter

The expert positions this quarter are not symmetrical. The sports-medicine reviewers (Mayfield, Rahman, Villegas Meza) agree on the gap: animal data only, no human RCT, no established dosing. Topol raises a class-level safety signal (cancer risk from broad GH stimulation) that the orthopaedic papers do not address. Attia places CJC-1295 above the worst-evidence peptides but below the threshold where he considers use justified. The regulatory shift -- removal from Category 2 -- has been widely reported as "re-legalisation," but credentialed pharmacists and FDA-law attorneys caution that the legal picture remains genuinely uncertain until the PCAC review concludes and formal rulemaking follows.

The foundational human data for CJC-1295 remains what it was in 2006: two small Phase 1 studies in healthy adults by the ConjuChem team^[9][10]. No Phase 2 or Phase 3 trial has been completed. No regulator in our coverage area has approved CJC-1295 for any indication. Readers considering this compound should discuss it with a clinician who knows their case. For background on the molecule itself, see the CJC-1295 page on this site.